KCM
COGT icon

Kynam Capital Management’s Cogent Biosciences COGT Stock Holding History

Kynam Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$142M Sell
3,667,097
-370,234
-9% -$13M 7.84% 4
2026
Q1 		$155M Sell
4,037,331
-2,127,892
-35% -$78.6M 9.59% 4
2025
Q4 		$219M Sell
6,165,223
-1,720,949
-22% -$48.4M 13.99% 1
2025
Q3 		$113M Sell
7,886,172
-606,385
-7% -$7.18M 8.43% 4
2025
Q2 		$61M Sell
8,492,557
-612,443
-7% -$3.4M 6.56% 8
2025
Q1 		$54.5M Hold
9,105,000
– – 4.58% 9
2024
Q4 		$71M Sell
9,105,000
-134,731
-1% -$1.34M 4.2% 8
2024
Q3 		$99.8M Sell
9,239,731
-20,654
-0.2% -$201K 7.65% 5
2024
Q2 		$78.1M Buy
9,260,385
+760,385
+9% +$5.77M 6.02% 7
2024
Q1 		$57.1M Buy
8,500,000
+2,645,234
+45% +$16.4M 5.98% 5
2023
Q4 		$34.4M Buy
5,854,766
+3,644,641
+165% +$27.9M 3.81% 9
2023
Q3 		$21.5M Buy
2,210,125
+592,734
+37% +$7.03M 3.52% 10
2023
Q2 		$19.1M Buy
1,617,391
+1,217,417
+304% +$14M 2.63% 11
2023
Q1 		$4.32M Sell
399,974
-394,075
-50% -$5.04M 0.56% 23
2022
Q4 		$9.18M Sell
794,049
-191,106
-19% -$2.37M 1.41% 15
2022
Q3 		$14.7M Sell
985,155
-14,845
-1% -$203K 3.1% 12
2022
Q2 		$9.02M Buy
+1,000,000
New +$6.83M 2.3% 13
2022
Q1 		– Sell
-150,000
Closed -$1.29M – 35
2021
Q4 		$1.29M Buy
+150,000
New +$1.3M 0.69% 27

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kynam Capital Management's COGT Position: Q2 2026 in Review

Kynam Capital Management reduced its Cogent Biosciences (COGT) stake by 9.2% in Q2 2026, selling an estimated $13M and leaving 3,667,097 shares worth $142M. The position accounts for 7.84% of the portfolio, ranked #4.

Kynam Capital Management first reported a position in COGT in Q4 2021 and has held it in 18 quarters since. The position peaked at $219M in Q4 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Kynam Capital Management held 3,667,097 shares of Cogent Biosciences worth $142M as of Q2 2026.
  • Kynam Capital Management sold 370,234 Cogent Biosciences shares in Q2 2026, an estimated $13M.
  • Cogent Biosciences made up 7.84% of Kynam Capital Management's portfolio in Q2 2026, its #4 holding.
  • Kynam Capital Management first reported a position in Cogent Biosciences in Q4 2021 and has held it in 18 quarters since.
  • Kynam Capital Management's Cogent Biosciences position peaked at $219M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Kynam Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.